Genscript Bio (01548) rose nearly 4%, as of the time of publication, up 3.79% to HK$12.04, with a turnover of 39.6598 million HK dollars.
According to the WiseNews app, Genscript Bio (01548) rose nearly 4%, up 3.79% to HK$12.04, with a turnover of 39.6598 million HK dollars at the time of publication.
On the news front, Genscript Bio recently announced that on August 27, the National Medical Products Administration (NMPA) approved the New Drug Application (NDA) for cilta-cel submitted by its non-wholly owned subsidiary, Nanjing Legend Biotech Co., Ltd., for the treatment of eligible adult patients with relapsed or refractory multiple myeloma.
It is reported that cilta-cel is a chimeric antigen receptor T-cell (CAR-T) therapy targeting BCMA developed by Legend Biotech, which uses transgenic CAR to modify the patient's own T cells to recognize and eliminate cells expressing BCMA. According to Johnson & Johnson's second-quarter financial report, the drug achieved global sales of $343 million in the first half of this year, an 81.5% year-on-year increase.